These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 30392555)

  • 1. False-Positive DaTscan Features With Methylphenidate and Phentermine Therapy.
    Huynh KN; Nguyen BD
    Mayo Clin Proc; 2018 Nov; 93(11):1690-1691. PubMed ID: 30392555
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.
    Carter LP; Henningfield JE; Wang YG; Lu Y; Kelsh D; Vince B; Sellers E
    J Psychopharmacol; 2018 Dec; 32(12):1351-1361. PubMed ID: 30269642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.
    Leonard BE; McCartan D; White J; King DJ
    Hum Psychopharmacol; 2004 Apr; 19(3):151-80. PubMed ID: 15079851
    [No Abstract]   [Full Text] [Related]  

  • 5. Methylphenidate significantly alters the functional coupling between the prefrontal cortex and dopamine neurons in the ventral tegmental area.
    Dela Peña IC; Shen G; Shi WX
    Neuropharmacology; 2018 Mar; 131():431-439. PubMed ID: 29339293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinsonian patients report blunted subjective effects of methylphenidate.
    Persico AM; Reich S; Henningfield JE; Kuhar MJ; Uhl GR
    Exp Clin Psychopharmacol; 1998 Feb; 6(1):54-63. PubMed ID: 9526146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug dependence and methylphenidate].
    Sora I; Ikari M; Ikeda K
    Seishin Shinkeigaku Zasshi; 2008; 110(10):941-5. PubMed ID: 19278070
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron.
    Ding YS; Fowler JS; Volkow ND; Gatley SJ; Logan J; Dewey SL; Alexoff D; Fazzini E; Wolf AP
    Synapse; 1994 Oct; 18(2):152-60. PubMed ID: 7839313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Visual hallucinations caused by methylphenidate].
    Tomás Vila M; Izquierdo Quevedo FJ; Cerdán Vera MT; Fernández A; Artés Figueres M; Revert Gomas M
    An Pediatr (Barc); 2010 Mar; 72(3):229-30. PubMed ID: 20097145
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hallucinations caused by the introduction of methylphenidate at low doses].
    Aguilera-Albesa S; Yoldi-Petri ME; Molins-Castiella T; Durá-Travé T
    Rev Neurol; 2010 Aug; 51(4):254-5. PubMed ID: 20648469
    [No Abstract]   [Full Text] [Related]  

  • 11. The Neurocognitive Cost of Enhancing Cognition with Methylphenidate: Improved Distractor Resistance but Impaired Updating.
    Fallon SJ; van der Schaaf ME; Ter Huurne N; Cools R
    J Cogn Neurosci; 2017 Apr; 29(4):652-663. PubMed ID: 27779907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate.
    Cheng G; Morley JF
    Clin Nucl Med; 2014 Feb; 39(2):211-3. PubMed ID: 24300364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and Atypical Parkinsonian syndromes using DaTSCAN® SPECT.
    Davidsson A; Georgiopoulos C; Dizdar N; Granerus G; Zachrisson H
    Ann Nucl Med; 2014 Nov; 28(9):851-9. PubMed ID: 24997753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole Treatment of Compulsive Behaviors Associated With Methylphenidate in a Child With Down Syndrome.
    Sertdemir M; Akça ÖF
    J Clin Psychopharmacol; 2018 Apr; 38(2):159-161. PubMed ID: 29389777
    [No Abstract]   [Full Text] [Related]  

  • 15. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain.
    Federici M; Geracitano R; Bernardi G; Mercuri NB
    Biol Psychiatry; 2005 Feb; 57(4):361-5. PubMed ID: 15705351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acute administration of phentermine, alone or in combination with dexfenfluramine, on pain reactivity in the adult rat.
    Wellman PJ
    Pharmacol Biochem Behav; 2008 Sep; 90(3):339-43. PubMed ID: 18462783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.
    Schrantee A; Tremoleda JL; Wylezinska-Arridge M; Bouet V; Hesseling P; Meerhoff GF; de Bruin KM; Koeleman J; Freret T; Boulouard M; Desfosses E; Galineau L; Gozzi A; Dauphin F; Gsell W; Booij J; Lucassen PJ; Reneman L
    PLoS One; 2017; 12(2):e0172776. PubMed ID: 28241065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine.
    Frankl JA; Bose S; Kuo PH
    J Nucl Med Technol; 2018 Jun; 46(2):149-150. PubMed ID: 29273699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
    Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM
    Synapse; 2002 Mar; 43(3):181-7. PubMed ID: 11793423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high".
    Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Dewey SL; Hitzemann R; Gifford AN; Pappas NR
    J Pharmacol Exp Ther; 1999 Jan; 288(1):14-20. PubMed ID: 9862747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.